Here are two stocks with buy rank and strong momentum characteristics for investors to consider today, July 7th:Verona Pharma (VRNA) : This company which is focused on developing and commercializing innovative therapeutics for the treatment of patients burdened with chronic respiratory diseases with significant unmet medical needs, has a Zacks Rank #1(Strong Buy), and witnessed the Zacks Consensus Estimate for its current year earnings increasing 37.5% over the last 60 days.Verona Pharma’s shares gained 69% ...

POLAND - 2025/02/22: In this photo illustration, the Jazz Pharmaceuticals company logo is seen ... More displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesJazz Pharmaceuticals (NASDAQ: JAZZ) is currently trading at approximately $110, having decreased by 11% year-to-date, even after a significant positive development with the conditional European Commission Marketing Authorization for Ziihera (zanidatamab) aime ...

– National Footprint of NEXICART-2 Trial Sites Expanded – – On track for first Biologics License Application (BLA) approved cell therapy in unaddressed orphan indication – – NEXICART-2 interim results were presented at ASCO 2025 – LOS ANGELES, CA, July 07, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today announced accelerated U.S. NEXICART- ...

Jazz Pharmaceuticals plc's (NASDAQ: JAZZ ) stock price has continued to fluctuate between $97 and $120 over the past three months, even as it has made significant progress in developing its oncology franchise.With over two decades of dedicated experience in investment, Allka Research has been a guiding force for individuals seeking lucrative opportunities. Its conservative approach sets it apart, consistently unearthing undervalued assets within the realms of ETFs, commodities, technology, and pharmaceutica ...

KalVista Pharmaceuticals (KALV) FDA Announcement July 07, 2025 08:30 AM ET Speaker0 Good day and thank you for standing by. Welcome to the Calvista Pharmaceuticals FDA Approval Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. Please be advised that today's conference is being recorded. Speaker1 I would now like to hand Speaker0 the conference over to Ryan Baker, Head of Investor Relations. Please go ahead. Speaker2 ...

In an ongoing Phase 1 trial published in Nature Medicine, MB-101 was well-tolerated and 50% of patients achieved stable disease or better with two partial responses and two complete responses lasting 7.5 and 66+ months, respectively Preclinical data support a novel combination of MB-101 (IL13Rα2‐targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus) to optimize clinical results FDA previously granted Orphan Drug Designation to Mustang for MB-108 for the treatment of malignant glioma WORCESTER, Mas ...

Includes Conduit’s first composition of matter patent filing for AZD5658 and multiple new combination filings for AZD1656 and AZD5658Patents derived from AI-led analysis conducted in partnership with Sarborg Limited NAPLES, Fla. and CAMBRIDGE, United Kingdom, July 07, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit" or the “Company”) today announces the filing of four new patent applications relating to its key assets AZD1656 and AZD5658, including the Company’s first patent fi ...

摘要 3、 "反内卷"行情持续，周期板块逆势上涨，从历史行情看未来主线，如何做好资产配置？ 真话白话说财经，理财不说违心话 --这是第1381 篇白话财经- - 今天，A股三大指数震荡分化，沪指收红，创业板指跌超1%。不过个股涨多跌少，有超3200只个股上涨。 (图片来源：东方财富APP，统计截至2025/7/7，不作投资推荐） 两市成交额出现缩量，为1.21万亿元，盘面上，电力、地产、传媒等板块逆势上涨，创新药、贵金属等板块跌幅居前。 1、今天，A股三大指数出现震荡，沪指收红，创业板指跌超1%，个股涨多跌少，发生了什么？ 2、 强化高频交易监管，三大交易所新规正式实施，影响几何？A股冲击3500点能否成功？ 7月7日起，沪深北三大交易所《程序化交易管理实施细则》正式开始实施，将加强程序化交易监测监控，强化高频交易监管。 短期来看， 新规限制高频交易，使得 中小盘股活跃度下降，间接影响创业板流动性。 但长期来看，前海开源基金首席经家杨德龙表示，新规的发布有利于减少程序化交易对市场波动的影响、提振投资者信心，推动资本市场长期健康发 展。 2、板块分化，电力受利好政策上涨，科技承压。 今天，创新药 、消费电子等科 ...

Planned submission of IND application in 2025; Phase 1 clinical trial to follow if IND application approved No new PTSD drug approvals in the U.S. in nearly 25 years; large potential addressable market for SPC-15 worldwide SARASOTA, FL, July 07, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that it expects to receive data from the additional preclini ...

《科创板日报》7日讯，近日，DeepMind旗下的药物研发公司Isomorphic Labs正准备开始在人体上测试 其人工智能设计的药物。Isomorphic Labs于2021年从DeepMind分拆出来，一直处于将AI融入药物研发 的前沿。该公司利用先进的机器学习算法分析海量生物数据，识别潜在的药物靶点，并设计出能够有效 治疗多种疾病的新型化合物。 DeepMind旗下Isomorphic Labs将启动AI设计药物的人体试验 ...